From what I gather, the following peer-reviewed articles should be published in 2013:
- Moffitt murine model data -- Q3 and
- Full MM Phase 2 trial results (Provectus & PIs) -- Q3/Q4.
One or more of the following also could be in peer-reviewed publications this year:
- PV-10 and sorafenib drug-drug metabolic interaction data (Provectus),
- Phase 1 feasibility trial results (Moffitt),
- Liver cancer Phase 1 trial data (Provectus & PIs),
- Dermatology mechanism of action and toxicity study results (unnamed, for now),
- A special publication about notable immunologic activity observed in the MM Phase 2 trial (Provectus & PIs),
- Data from and case studies about compassionate use program patients (CUP site physicians & Provectus),
- Meta analysis of the PH-10 dermatology trials' data (Provectus & PIs),
- A follow-up to "A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series" (investigator initiated) describing Dr. Foote's 25+ patient trial, and
- A follow-up to "Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma," (investigator initiated).
No comments:
Post a Comment